Bibliografía

American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1999; 22(suppl 1): S27-S31.( RB1)

American Diabetes Association.Diabetic Nephropathy. Diabetes Care 1999; 22 (suppl 1): S66-S69. (RB2)

Amoah E, Glickman JL, Malchoff CD et al. Clinical identification of non diabetic renal disease in diabetic patients with type 1 and type 2 disease presenting with renal dysfunction. Am J Nephrol 1988; 8: 204-11.(RB3)

Annonymus. Summary of the second report of the National Cholesterol Education Program (NCEP)Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel II) JAMA 1993; 269: 3015-3023 (RB51)

Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641-50. (RB4)

Canadian Medical Association.1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998; 159 (8 suppl). (RB5)

Chalmers J et al. WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 1999, 17:151-185. (RB6)

Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-19. (RB7)

Corchado Y, Sanchez Mata P, Duarte C et al. Estudio de microalbuminuria en pacientes diabéticos tipo 2. Atención Primaria 1991; 8: 886-90 (RB8)

Desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med. 1999; 16: 716-30. (RB9)

Diamond JM. Human evolution: Diabetes running wild. Nature 1992; 357: 362-3(RB10)

Esmatges E, Castell C, Gonzalez A T. Epidemiology of renal involvement in type 2 diabetics in Catalonia. Diabetes Res Clin Pract 1996; 32: 157-63(RB11)

Estudio Diamante. Renal involvement in type 1 diabetes in Spain. Diabetes Res Clin Pract 1997; 38: 129-37(RB12)

Gaede P, Vedel P, Parving HH Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-22.(RB13)

Gall M, Rossing P, Skott P et al. Prevalence of micro and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 diabetic patients.Diabetologia 1991; 34: 655-661(RB14)

Gomez FJ, Luño J, Garcia S, Valderrábano F. ¿Por qué es necesaria la remisión precoz a la consulta del nefrólogo de los pacientes con nefropatía diabética? Atención Primaria 1999; 23:503-4(RB15)

Gonzalez, M.T., Castell C., Esmatjes E. Et al. Insuficiencia renal secundaria a nefropatía diabética. Revisión de las características de los pacientes diabéticos que iniciaron diálisis en Cataluña en 1994. Rev. Clin. Esp. 1999; 199: 8-12.(RB16)

Guía para el tratamiento de la diabetes tipo 2 en la Atención Primaria (3ª ed). Ed. Gedaps. 2000. (RB17)

Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney International 1999; 55: 1-28. (RB18)

Jameel N, Pughja A, Mitchell B, Stern M. Dietary protein intake in not correlated with clinical proteinuria in NIDDM. Diabetes Care 1992; 15: 178-83 (RB19)

Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis. Annals of Internal Medicine.1993; 118: 129-138. (RB20)

Lazarus J.M., Brenner B M, Insuficiencia renal crónica. En: Harrison, Principios de Medicina Interna (14ª ed. Esp.) Madrid: McGraw-Hill.Interamericana. 1998; 1720-1727. (RB21)

Lewis EJ, Hunsicker LG, Bain RP, Rodhe RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62. (RB22)

Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of endstage failure from diabetic nephropaty type 2: an epidemiological analysis. Nephrol Dial Transplant 1995; 10: 462-7.(RB23)

Lovell HG. Are angiotensin converting enzyme inhibitors useful for normotensive diabetic patients with microalbuminuria?. Cochrane Database of Systematic Reviews. Issue 2, 1999.(RB24)

Mata M. Microalbuminuria y diabetes. FMC 1994; 1: 104-11 (RB25)

Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease: With emphasis on the stage of incipient diabetic nephropaty. Diabetes 1983; 32 (suppl 2): 64-78. (RB26)

Mogensen CE, Keane WF, Bennet PH, Jerums G, Parving HH Passa P. Prevención de la nefropatía diabética con especial referencia a la microalbuminuria. Lancet (ed. Esp.) 1996; 28:201-206. (RB27)

Mogensen CE. Microalbuminuria: Un marcador de lesión orgánica. London. Science Press 1994(RB28)

Parving HH, Gall MA, Skoit P. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-62 (RB29)

Parving HH, Tarnow L, Rossing P. Renal protection in diabetes-an emerging role for calcium antagonists. Cardiology 1997; 88(suppl 3): 56-62.(RB30)

Parving HH. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998; 41: 745-759. (RB31)

Passa P. Diabetic nephropaty in the NIDDM patient on the interface between diabetology and nephrology. What do we have to improve? Nephrol Dial Transplant 1997; 12: 1316-7(RB32)

Pedrini M, Levey A, Lau J, Chalmers T, Wang P. The Effect of Dietary Protein Restriction on the Progression of Diabetic and Nondiabetic Renal Diseases: A Meta-Analysis. Ann Internn Med 1996; 124: 627-32(RB33)

Pomerleau J, Verdy M, Garrel D, Nadeau M. Effect of protein intake on glycaemic control and renal function in type 2 diabetes mellitus. Diabetologia 1993; 36: 829-34(RB34)

Pommer W et al. There is a room for improvement of preterminal care in diabetic patients with end-stage renal faillure: The epidemiological evidence in Germany. Nephrol Dial Transplant 1997; 12: 1318-20 (RB35)

Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter J, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630-635.(RB36)

Ravid M, Lang R, Rachmani R, Lishner M. Long-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non-Insulin-dependent Diabetes Mellitus. Arch Intern Med 1996; 156: 286-289.(RB37)

Ritz E, Koch M, Fliser D, Schwenger V. How can We Improve Prognosis in Diabetic Patients With End-Stage Renal Disease?. Diabetes Care 1999; 22: B80-83.(RB38)

Ritz E, Reinhold S. Nephropaty in Patients with Type 2 Diabetes Mellitus. N Engl J Med 1999; 341: 1127-33(RB39)

Ritz E, Rychlik I, Locatelli F, Halimi S. End-Stage Renal Failure in Type 2 Diabetes: A Medical Catastrophe of Worlwide Dimensions. Am J Kidney Dis. 1999; 34: 795-808.(RB40)

Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999; 245: 111-26.(RB41)

Salvetti A, Mattei P, Sudano I. Renal Protection and Antihypertensive Drugs. Drugs 1999; 57: 665-693.(RB42)

Scottish Intercollegiate Guidelines Network. Management of Diabetic Renal Disease. Edimburgh 1997.(RB43)

Sociedades Españolas de Diabetes, Endocrinología, Medicina Familiar y Comunitaria y Nefrología. Documento de consenso sobre pautas de detección y tratamiento de la nefropatía diabética en España. Aten Primaria 1998; 21: 471-476.(RB44)

Solanas JV, Soler JM, Ros A, Fos V, Vento D, Prósper M. Validez de los métodos semicuantitativo de cribado de la microalbuminuria en la diabetes mellitus. Aten Primaria 1998; 22: 631-635.(RB45)

The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92 (RB50)

The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health (JNC-VI). Arch Intern Med 1997; 157:2413-2446.(RB46)

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.(RB47)

Toeller M, Buyken A, Heitkamp G et al. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 1997; 40: 1219-26(RB48)

Zmiron D, Benhamon PY,Cordonier D et al. Diabetes mellitus prevalence among dyalised patients in France (UREMIDIAB Study). Neprhol Dial Transplant 1992; 7: 1092-7(RB49)


Anamensis · Antecedentes · Enfermedad actual · Cuestionario · Conclusiones · Bibliografía

Página inicial 

Puntuación Conclusiones